Quick Answer
MapLight Therapeutics, Inc. reported Net Income of -$161.15 million for fiscal year 2025.
MapLight Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$161.15M | -107.7% |
| 2024 | -$77.58M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$29.42M | -54.7% | +1.4% |
| June 30, 2025 | -$29.85M | -62.2% | -33.6% |
| March 31, 2025 | -$22.34M | -18.0% | -17.5% |
| September 30, 2024 | -$19.02M | — | -3.3% |
| June 30, 2024 | -$18.40M | — | +2.8% |
| March 31, 2024 | -$18.93M | — | — |
- MapLight Therapeutics, Inc. showed a decrease of -107.7% in Net Income compared to the prior fiscal year.
- Over the 2024–2025 period, MapLight Therapeutics, Inc.’s net income has declined by 107.7% (from -$77.58 million to -$161.15 million).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: